Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling

被引:10
作者
Barbacki, Ariane [1 ]
Baron, Murray [1 ]
Wang, Mianbo [1 ]
Zhang, Yuqing [2 ]
Stevens, Wendy [3 ]
Sahhar, Joanne [4 ]
Proudman, Susanna [5 ]
Nikpour, Mandana [6 ]
Man, Ada [7 ]
机构
[1] Lady Davis Inst Med Res, Montreal, PQ, Canada
[2] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[3] St Vincents Hosp Melbourne, Fitzroy, Vic, Australia
[4] Monash Hlth, Clayton, Vic, Australia
[5] Royal Adelaide Hosp, North Terrace, Adelaide, SA, Australia
[6] Univ Melbourne, St Vincents Hosp Melbourne, Fitzroy, Vic, Australia
[7] Univ Manitoba, Winnipeg, MB, Canada
基金
加拿大健康研究院; 英国医学研究理事会;
关键词
SCLERODERMA RENAL CRISIS; CIGARETTE-SMOKING; SINGLE-CENTER; SAS PROCEDURE; LUNG-DISEASE; RISK-FACTORS; MORTALITY; SURVIVAL; PREDICTION; AMERICAN;
D O I
10.1002/acr.24873
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Systemic sclerosis (SSc) is an autoimmune disease characterized by progressive organ damage, which can be measured using the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI). We aimed to identify whether distinct trajectories of damage accrual exist and to determine which variables are associated with different trajectory groups. Methods Incident cases of SSc (<2 years) were identified in the Australian Scleroderma Interest Group and Canadian Scleroderma Research Group prospective registries. Group-based trajectory modeling was used to identify SCTC-DI trajectories over the cohort's first 5 annual visits. Baseline variables associated with trajectory membership in a univariate analysis were examined in multivariable models. Results A total of 410 patients were included. Three trajectory groups were identified: low (54.6%), medium (36.2%), and high (10.3%) damage. Patients with faster damage accrual had higher baseline SCTC-DI scores. Older age (odds ratio [OR] 1.57 [95% confidence interval (95% CI) 1.18-2.10]), male sex (OR 2.55 [95% CI 1.10-5.88]), diffuse disease (OR 6.7 [95% CI 2.57-17.48]), tendon friction rubs (OR 5.4 [95% CI 1.86-15.66]), and elevated C-reactive protein level (OR 1.98 [95% CI 1.49-2.63]) increased the odds of being in the high-damage group versus the reference (low damage), whereas White ethnicity (OR 0.31 [95% CI 0.12-0.75]) and anticentromere antibodies (OR 0.24 [95% CI 0.07-0.77]) decreased the odds. Conclusion We identified 3 trajectories of damage accrual in a combined incident SSc cohort. Several characteristics increased the odds of belonging to worse trajectories. These findings may be helpful in recognizing patients in whom early aggressive treatment is necessary.
引用
收藏
页码:640 / 647
页数:8
相关论文
共 51 条
[1]   Blood Pressure Trajectories in Early Adulthood and Subclinical Atherosclerosis in Middle Age [J].
Allen, Norrina B. ;
Siddique, Juned ;
Wilkins, John T. ;
Shay, Christina ;
Lewis, Cora E. ;
Goff, David C. ;
Jacobs, David R., Jr. ;
Liu, Kiang ;
Lloyd-Jones, Donald .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (05) :490-497
[2]  
Apipattarakul Ruethairat, 2018, Clin Exp Rheumatol, V36 Suppl 113, P76
[3]  
Arrandale V., 2006, USE SAS P TRAJ SAS P
[4]   Clinical and Genetic Factors Predictive of Mortality in Early Systemic Sclerosis [J].
Assassi, Shervin ;
del Junco, Deborah ;
Sutter, Kari ;
McNearney, Terry A. ;
Reveille, John D. ;
Karnavas, Andrew ;
Gourh, Pravitt ;
Estrada-Y-Martin, Rosa M. ;
Fischbach, Michael ;
Arnett, Frank C. ;
Mayes, Maureen D. .
ARTHRITIS CARE & RESEARCH, 2009, 61 (10) :1403-1411
[5]   Office capillaroscopy in systemic sclerosis [J].
Baron, Murray ;
Bell, Mary ;
Bookman, Arthur ;
Buchignani, Maura ;
Dunne, James ;
Hudson, Marie ;
Jerome, Dana ;
Johnson, Sindhu R. ;
Jones, Niall ;
Kaminska, Elzbieta ;
Lupton, Terri ;
Mathieu, Jean-Pierre ;
Pope, Janet ;
Steele, Russell ;
Taillefer, Suzanne .
CLINICAL RHEUMATOLOGY, 2007, 26 (08) :1268-1274
[6]   Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis [J].
Becker, Mike ;
Graf, Nicole ;
Sauter, Rafael ;
Allanore, Yannick ;
Curram, John ;
Denton, Christopher P. ;
Khanna, Dinesh ;
Matucci-Cerinic, Marco ;
Pena, Janethe de Oliveira ;
Pope, Janet E. ;
Distler, Oliver ;
Matucci-Cerinic, Marco ;
Guiducci, Serena ;
Walker, Ulrich ;
Jaeger, Veronika ;
Bannert, Bettina ;
Lapadula, Giovanni ;
Becvarare, Radim ;
Cutolo, Maurizio ;
Valentini, Gabriele ;
Siegert, Elise ;
Rednic, Simona ;
Allanore, Yannick ;
Montecucco, C. ;
Carreira, Patricia E. ;
Novak, Srdan ;
Czirjak, Laszlo ;
Varju, Cecilia ;
Chizzolini, Carlo ;
Allai, Daniela ;
Kucharz, Eugene J. ;
Cozzi, Franco ;
Rozman, Blaz ;
Mallia, Carmel ;
Gabrielli, Armando ;
Bancel, Dominique Farge ;
Airo, Paolo ;
Hesselstrand, Roger ;
Martinovic, Duska ;
Balbir-Gurman, Alexandra ;
Braun-Moscovici, Yolanda ;
Hunzelmann, Nicolas ;
Pellerito, Raffaele ;
Caramaschi, Paola ;
Black, Carol ;
Damjanov, Nemanja ;
Henes, Joerg ;
Ortiz Santamaria, Vera ;
Heitmann, Stefan ;
Seidel, Matthias .
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (09) :1242-1248
[7]   Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group [J].
Bissell, Lesley-Anne ;
Yusof, Md Yuzaiful Md ;
Buch, Maya H. .
RHEUMATOLOGY, 2017, 56 (06) :882-895
[8]   Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria [J].
Boonstra, Maaike ;
Ninaber, Maarten K. ;
Marsan, Nina Ajmone ;
Huizinga, Tom W. J. ;
Scherer, Hans Ulrich ;
de Vries-Bouwstra, Jeska K. .
RHEUMATOLOGY, 2019, 58 (04) :730-732
[9]   Distinctive clinical phenotype of anti-centromere antibody-positive diffuse systemic sclerosis [J].
Caetano, Joana ;
Nihtyanova, Svetlana, I ;
Harvey, Jennifer ;
Denton, Christopher P. ;
Ong, Voon H. .
RHEUMATOLOGY ADVANCES IN PRACTICE, 2018, 2 (01) :1-6
[10]  
Callejas-Moraga EL, 2019, CLIN EXP RHEUMATOL, V37, pS41